Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

Rhea-AI Summary

Soleno Therapeutics (NASDAQ: SLNO) will present multiple studies at the 2022 European Congress of Endocrinology in Milan, Italy, from May 21-24. The presentations include updates on the long-term safety of Diazoxide Choline Extended-Release (DCCR) in treating Prader-Willi syndrome (PWS). Key presentations are scheduled for May 21 and May 22, with notable findings by Dr. Evelien Gevers and the DESTINY PWS Investigators. Further details and copies of the posters will be available on Soleno's website post-presentation.

Positive

• Presence at a prominent medical congress, highlighting the company's ongoing commitment to research.
• Presentation of crucial data regarding DCCR, potentially advancing its profile in PWS treatment.

Negative

• None.

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy.

Details of the presentations are as follows:

2022 European Congress of Endocrinology (ECE)

Title:	DCCR Update
Format:	Presentation at the International Prader-Willi syndrome Meeting 2022 organized by INfoRMEd – PWS (the International Netwrok for Research, Managament and Education on adults with PWS) and the European Society of Endocrinology
Presenter:	Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators
Date	Saturday, May 21, 2022
Time:	12:10 – 12:30 PM CET

Title:	Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format:	E-Poster -- Programme Code: EP360 / Submission Number 2044
Presenter:	Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators

Title:	Comparison of hyperphagia and problem behaviors in participants with Prader-Willi syndrome (PWS) receiving Diazoxide Choline Extended-Release (DCCR) with matched participants in PATH for PWS (PfPWS)
Format:	Poster -- Programme Code: P77 / Submission Number 789
Presenter:	Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators and the PATH for PWS Investigators
Date:	Sunday, May 22, 2022

The copy of the posters will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

What presentations will Soleno Therapeutics make at the 2022 European Congress of Endocrinology?

Soleno Therapeutics will present on DCCR's long-term safety in PWS and comparative studies on hyperphagia and behavior at the 2022 European Congress of Endocrinology.

When is Soleno Therapeutics presenting at the 2022 European Congress of Endocrinology?

Soleno Therapeutics' presentations are scheduled for May 21 and 22, 2022.

Where can I find the presented materials from Soleno Therapeutics?

Copies of the posters presented by Soleno Therapeutics will be available in the Investors section on their website after the event.

What is the significance of DCCR for Prader-Willi syndrome as presented by Soleno Therapeutics?

DCCR represents a novel therapeutic avenue for Prader-Willi syndrome, with ongoing Phase 3 clinical trials exploring its efficacy and safety.

Who is presenting the data for Soleno Therapeutics at the conference?

Dr. Evelien Gevers will present on behalf of the DESTINY PWS Investigators.